PEGylated insulin Lispro (LY2605541): clinical overview of a new long-acting basal insulin analog in the treatment of Type 2 diabetes mellitus

References

• International Diabetes Federation. Diabetes Atlas. 2013.update. Available from: www.idf.org/diabetesaltas/6e/Update2013
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42
   PubMed Web of Science ®Google Scholar
• Scott DA, Fisher AM. Studies on insulin with protamine. J Pharmacol Exp Ther 1936;58:78-92
   Google Scholar
• Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab 1946;1:60-73
   Google Scholar
• Markussen J, Damgaard U, Jørgensen KH, et al. Human monocomponent insulin. Chemistry and characteristics. Acta Med Scand Suppl 1983;671:99-105
   PubMedGoogle Scholar
• Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23:813-19
   PubMed Web of Science ®Google Scholar
• Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir: a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-504
   PubMed Web of Science ®Google Scholar
• Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29:2104-14
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Bottcher SG, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
   PubMed Web of Science ®Google Scholar
• Hansen RJ, Cutler GBJr, Vick A, et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin (abstract 896-B). Diabetes 2012;61(Suppl 1):A228
   Google Scholar
• Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care 2009;32(Suppl 2):S253-9
   PubMed Web of Science ®Google Scholar
• Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 2012;166:159-66
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23-8
   PubMed Web of Science ®Google Scholar
• Lopez Stewart G, Tambascia M, Rosas Guzman J, et al. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica 2007;22:12-20
   PubMed Web of Science ®Google Scholar
• Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ 2012;15:77-86
   PubMedGoogle Scholar
• Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-9
   PubMed Web of Science ®Google Scholar
• Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:1607-19
   PubMed Web of Science ®Google Scholar
• Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab 2013;15:978-86
   PubMed Web of Science ®Google Scholar
• Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-507
   PubMed Web of Science ®Google Scholar
• Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-71
   PubMed Web of Science ®Google Scholar
• Onishi Y, Park SW, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Invest 2013;4:605-12
   PubMed Web of Science ®Google Scholar
• Jørgensen S, Vaag A, Langkjaer L, et al. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. BMJ 1989;299:415-19
   PubMed Web of Science ®Google Scholar
• Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-5
   PubMed Web of Science ®Google Scholar
• Heinemann L Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-5
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Levemir. EPAR Scientific Discussion. 15 August 2006. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000528/WC500036658.pdf
   Google Scholar
• Koehler G, Treiber G, Wutte A, et al. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab 2014;16:57-62
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-8
   PubMed Web of Science ®Google Scholar
• Meneghini L, Kesavadev J, Demissie M, et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:729-36
   PubMed Web of Science ®Google Scholar
• Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, non-inferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008;51:408-16
   PubMed Web of Science ®Google Scholar
• Suh DC, Aagren M. Cost-effectiveness of insulin detemir: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2011;11:641-55
   PubMed Web of Science ®Google Scholar
• Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006;37:495-501
   PubMed Web of Science ®Google Scholar
• Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29:2104-14
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-50
   PubMed Web of Science ®Google Scholar
• Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64
   PubMed Web of Science ®Google Scholar
• Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858-64
   PubMed Web of Science ®Google Scholar
• Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-42
   PubMed Web of Science ®Google Scholar
• Zinman B, DeVries JH, Bode B, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol 2013;1:123-31
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Del Prato S, Satman I, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab 2013;15:760-6
   PubMed Web of Science ®Google Scholar
• Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002;54:505-30
   PubMed Web of Science ®Google Scholar
• Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001;22:405-17
   PubMed Web of Science ®Google Scholar
• Owens RA, Lockwood JF, Dunbar JD, et al. In vitro characterization of novel basal insulin LY2605541: reduced mitogenecity and IGF-1R binding. Diabetes 2012;55(Suppl 1):S55; abstract
   Google Scholar
• Beals JM, Cutler GB, Vick A, et al. LY2605541: Leveraging hydrodynamic size to develop a novel basal insulin. Diabetologia 2012;55(Suppl 1):S23; abstract
   Google Scholar
• Sinha VP, Choi SL, Soon DKW, et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 2014;54:792-9
   PubMed Web of Science ®Google Scholar
• Paulsen E, Courtney JI, Duckworth W. The bioavailability, pharmacokinetics, and time action of regular and modified insulins in normal subjects. Diabetes 1979;28:640-5
   PubMed Web of Science ®Google Scholar
• Sinha VP, Howey DC, Choi SL, et al. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diab Obes Metab 2014;16:344-50
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycemic clamp studies. Diab Obes Metab 2007;9:648-59
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Choi SL, Lam ECQ, et al. Pharmacokinetics (PK) of the novel, long-acting basal insulin LY2605541 in subjects with varying degrees of renal function. Diabetologia 2012;55(Suppl 1):S379; abstract
   Google Scholar
• Moore MC, Smith MS, Sinha VP, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014;63:494-504
   PubMed Web of Science ®Google Scholar
• Henry RR, Mudaliar S, Choi SL, et al. Basal insulin Peglispro demonstrates preferential hepatic vs. peripheral action relative to insulin glargine in healthy subjects. Diabetes 2014;63(Suppl 1):A226; abstract
   Google Scholar
• Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-7
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes. Diabetes Care 2013;36:522-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Levemir: EPAR – Scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000528/WC500036658.pdf [Accessed 3 January 2015]
   Google Scholar
• Eli Lilly and Company, press release, May 12. 2014. Available from: http://lilly.mediaroom.com/index.php?s=9042&item=137302
   Google Scholar
• ClinicalTrials.gov. 2015. Available from: https://clinicaltrials.gov/ct2/results?term=ly2605541&pg=1
   Google Scholar
• Bergenstal RM, Rosenstock J, Bastyr EJ, et al. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. Diabetes Care 2014;37:659-65
   PubMed Web of Science ®Google Scholar
• Jacober SJ, Rosenstock J, Bergenstal et al. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes Obes Metab 2014;16:351-6
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company, press release. February 23 2015;https://investor.lilly.com/releasedetail.cfm?ReleaseID=897636
   Google Scholar